Search clinical trials for: KN046

Total 38 results

Peking University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

HER2 Positive Solid Tumor

China
Peking University Cancer Hospital & Institute

Not yet recruiting

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

HER2-positive Colorectal Cancer | HER2-positive Biliary Tract Cancer

China
Peking University

Not yet recruiting

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

HER2-positive Locally Advanced Resectable Gastric Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

China
Suzhou Kintor Pharmaceutical Inc,
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Solid Tumor

Taiwan
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma | Advanced Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Alphamab (Australia) Co Pty Ltd.

Unknown

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Suzhou Alphamab Co., Ltd.
Novotech (Australia) Pty Limited

Recruiting

A Study to Evaluate Effects of KN056 in Healthy Participants

Type 2 Diabetes

New Zealand
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Thymic Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

Squamous Non-small-cell Lung Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Thymic Carcinoma

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Breast Cancer | Gastric Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Breast Cancer | Gastric/Gastroesophageal Junction Cancer

United States
Peking University Cancer Hospital & Institute

Recruiting

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

The Efficacy and Safety of KN046 Combined With Axitinib

NSCLC

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Peking University

Completed

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

HER2-positive Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Changchun Intellicrown Pharmaceutical Co. LTD

Recruiting

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Advanced Solid Tumors

China
Maxinovel Pty., Ltd.

Not yet recruiting

A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

Advanced / Metastatic Solid Tumors
Peking University Cancer Hospital & Institute

Completed

The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

HCC

China
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Advanced Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer

China
Shanghai Chest Hospital
First Affiliated Hospital of Suzhou Medical College

Unknown

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Unknown

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Enrolling by invitation

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Recruiting

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Stomach Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

HER2-positive Metastatic Breast Cancer

China
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Non-Malignant Neoplasm

United States

Search clinical trials for: KN046

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations